TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson’s disease

Neural Regeneration Research

Volumn 11, Issue 5, 2016, Pages 698-701

  Binukumar, B K ^a   Pant, Harish C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Cyclin dependent kinase 5; MPTP; Neurodegeneration; Parkinson s disease; Therapeutic target; TP5 TFP5 TP5 peptide

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 5; CYTOCHROME C; INTERLEUKIN 1BETA; PROTEIN BCL 2; PROTEIN P25; THYMOPENTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; APOPTOSIS; CELL ACTIVATION; CELL DEATH; COGNITION; CYTOKINE PRODUCTION; DOPAMINE RELEASE; ENCEPHALITIS; GAIT; IMMUNOREACTIVITY; MACROGLIA; MICROGLIA; MPTP-INDUCED PARKINSONISM; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW;

EID: 84971475305     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.182681     Document Type: Review

References (40)

1. Alvira D, Tajes M, Verdaguer E, Acuña-Castroviejo D, Folch J, Camins A, Pallas M (2006) Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res 40: 251-258.
2. Amin ND, Albers W and Pant HC (2002) Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J Neurosci Res 67: 354-362.
3. Avraham E, Rott R, Liani E, Szargel R, Engelender S (2007) Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates the E3 ubiquitin-ligase activity and parkin aggregation. J Biol Chem 282: 12842-12850.
4. Bajaj NP, Al-Sarraj ST, Anderson V, Kibble M (1998) Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis. Neurosci Lett 245: 45-48.
5. Bajaj NP, al-Sarraj ST, Leigh PN, Anderson V, Miller CC (1999) Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilaments heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neurones in ALS. Prog Neuropsychopharmacol Biol Psychiatry 23: 833-850.
6. Binukumar B, Shukla V, Amin ND, Grant P, Bhaskar M, Skuntz S, Steiner J, Pant HC (2015) Peptide (TFP5/TP5), derived from Cdk5 activator P35, provides neuroprotection in the MPTP model of Parkinson's disease. Mol Biol Cell 26: 4478-4491
7. Brion JP, Couck AM (1995) Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 147: 1465-1476.
8. Chung YC, Kim SR, Jin BK (2010) Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 185: 1230-1237.
9. Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, Kim YS, Maeng S, Park SH, Jin BK (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187: 6508-6517.
10. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2: 14.
11. Floyd CC, Grant P, Gallant PE, Pant HC (1991) Principal neurofilament-associated protein kinase in squid axoplasm is related to casein kinase I. J Biol Chem 266: 4987-4994.
12. Grant P, Pant HC (2004) Topographic regulation of phosphorylation in giant neurons of the squid, Loligo pealei: role of phosphatases. J Neurobiol 58: 514-528.
13. Hill WD, Lee VM, Hurtig HI, Murray JM, Trojanowski JQ (1991) Epitopes located in spatially separate domains of each neurofilaments subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol 309: 150-160.
14. Ishiguro K, Omori A, Takamatsu M, Sato K, Arioka M, Uchida T (1992) Phosphorylationsites on tau by tau proteinkinaseI, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett 148: 202-206.
15. Julien JP (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30: 135-147.
16. Kesavapany S, Zheng YL, Amin N, Pant HC (2007) Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5. Biotechnol J 2: 978-987.
17. Lew J, Beaudette K, Litwin CM, Wang JH (1992) Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem 267: 13383-13390.
18. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403-1409.
19. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J (1997) p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol 94: 153-157.
20. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB (1996) Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A 93: 11173-11178.
21. Patrick GN, Zukerberg L, Nikolic M, de la Monte, S, Dikkes P, Tsai LH (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622.
22. Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, Park DS (2007) Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55: 37-52.
23. Sharma P, Barchi JJ, Jr Huang X, Amin ND, Jaffe H, Pant HC (1998) Site-specific phosphorylation of Lys-Ser-Pro repeat peptides from neurofilament H by cyclindependent kinase 5: structural basis for substrate recognition. Biochemistry 37: 4759-4766.
24. Shetty KT, Link WT, Pant HC (1993) cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. Proc Natl Acad Sci U S A 90: 6844-6848.
25. Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, Kesavapany S, Pant HC (2013). A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J 27: 174-186.
26. Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 13650-13655.
27. Smith PD, Mount MP, Shree R, Callaghan, Park DS (2006) Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26: 440-447.
28. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
29. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2002). Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16: 1474-1476.
30. Sundaram JR, Poore CP, Sulaimee NH, Pareek T, Asad AB, Rajkumar R, Cheong WF, Wenk MR, Dawe GS, Chuang KH, Pant HC, Kesavapany S (2013) Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J Neurosci 33: 334-343.
31. Takahashi M, Amin N, Grant P, Pant HC (1995) P13suc1 associates with a cdc2-like kinase in a multimeric cytoskeletal complex in squid axoplasm. J Neurosci 15: 6222-6229.
32. Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 523: 58-62.
33. Veeranna, Shetty KT, Takahashi M, Grant P, Pant HC (2000) Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain. Brain Res Mol Brain Res 76: 229-236.
34. Veeranna, Amin ND, Ahn NG, Jaffe H, Winters CA, Grant P, Pant HC (1998) Mitogen activated protein kinases (Erk1, 2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J Neurosci 18: 4008-4021.
35. Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV, Van Dam AM (2007) Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 42: 762-771.
36. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 6145-6150.
37. Zheng Y, Kesavapany S, Gravell M, Hamilton RS, Schubert M, Amin N, Albers W, Grant P, Pant HC (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. Embo J 24: 209-220.
38. Zheng YL, Li BS, Amin ND, Albers W, Pant HC (2002) A peptide derived from cyclindependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur J Biochem 269: 4427-4434.
39. Zheng YL, Li BS, Kanungo J, Kesavapany S, Amin N, Grant P, Pant HC (2007) Cdk5 Modulation of Mitogen-activated Protein Kinase Signaling Regulates Neuronal Survival. Mol Biol Cell 18: 404-413.
40. Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Kanungo J, Kesavapany S, Grant P, Albers W, Pant HC (2010) A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem 285: 34202-34212.